Need more information? Click here to connect with Kurin.
- Kurin, Inc. Reports Record Revenue for 2022
- Kurin, Inc. Announces Successful FDA Audit
- Kurin, Inc. Provides Update on Litigation Activity
- Kurin, Inc. Announces Full Scale Manufacturing of Push-button Needle
- Kurin, Inc. Statement Regarding Patent Litigation
- U.S. District Court Enters Judgment of No Infringement of Patent Asserted Against Kurin Inc. by Magnolia Medical Technologies, Inc.
- Kurin, Inc. Announces Launch of Its Proprietary Push-button Needle System
- Kurin, Inc. Announces Agreement with AllSpire Health GPO to Impact Contaminated Blood Cultures
- Kurin, Inc. Reports Record Sales for Q4 and Total 2021 Revenues
- Kurin, Inc. Reports Record Q3 Sales
- Kurin, Inc. announces UK clinical study results showing significant decrease in blood culture contaminations with the Kurin Lock™
- Kurin, Inc. Reports Record Sales Month
- Kurin, Inc. announces results on Kurin® efficacy from Oishei Children’s Hospital with zero blood culture contaminations
- Kurin, Inc. Announces Removal of Magnolia Patent Infringement Lawsuit Trial Date
- Kurin, Inc. announces peer-reviewed publication on Kurin® efficacy from Central Texas Veterans Health Care System
- Kurin, Inc. honored by MD Tech Review in annual listing of top Infection Control solutions
- Kurin, Inc. Named to Inc.’s Inaugural Best in Business List in the Prosperous and Thriving Category
- Kurin, Inc. Receives Allowance from United States Patent and Trademark Office of Additional Claims to its Innovative Blood Culture Collection Device.
- Kurin, Inc. Reports Record Revenues
- Kurin, Inc. Receives Supplier Horizon Award from Premier Inc.